Clinical Trial Update: MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) [Phase 3]

View source ↗

Summary

An update reports that the MOTION Phase 3 extension trial of safinamide as add-on to a dopamine agonist in early Parkinson's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: TERMINATED